ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has granted stock options for 17,000 common shares to one new employee as an employment inducement. The grant was approved by the Company's Compensation Committee under the Inducement Plan.
The options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining vesting monthly thereafter, contingent on continued employment. This grant was made under NYSE's Listed Company Manual Rule 303A.08 employment inducement exemption.
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has announced its participation in two upcoming investor conferences. The company's CEO Ameet Mallik will present at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, from 10:30-10:55 a.m. ET, and at the Jefferies Global Healthcare Conference on June 5, 2025, from 9:55-10:25 a.m. ET. Both presentations will be in a fireside chat format and available via webcast on the company's investor relations website, with replays accessible for approximately 30 days after each event.
The company will also present updated LOTIS-5 safety run-in data evaluating ZYNLONTA plus rituximab combination at EHA2025.
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has scheduled its first quarter 2025 financial results conference call and webcast for May 14, 2025, at 8:30 a.m. EDT. The company will present financial results and provide business updates during the call.
Participants can join via toll-free dial-in (1-800-836-8184 for North America and Canada) or through a live webcast available on the company's investor relations website. Pre-registration is recommended 10 minutes before the event. The webcast recording will be accessible for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) presented preclinical data for three exatecan-based antibody drug conjugates (ADCs) at the AACR Annual Meeting 2025. The key highlight was ADCT-242, targeting Claudin-6, which demonstrated potent antitumor activity in ovarian and non-small lung cancer models, with good tolerance up to 150 mg/kg in mice and 40 mg/kg in cynomolgus monkeys.
Additionally, ADCT-241, targeting PSMA, showed promising results in prostate cancer models with synergistic effects when combined with enzalutamide. The third ADC, HuB14-VA-PL2202, targeting ASCT2, exhibited potent antitumor activity in both solid and hematological cancer cell lines with good tolerability in preclinical studies.